159 related articles for article (PubMed ID: 30075519)
1. Failure of ulipristal acetate treatment as an indication for uterine malignancy: Two case reports.
Santoro A; Angelico G; Arciuolo D; Inzani F; Fanfani F; Romualdi D; Scambia G; Zannoni GF
Medicine (Baltimore); 2018 Aug; 97(31):e11532. PubMed ID: 30075519
[TBL] [Abstract][Full Text] [Related]
2. Inefficiency of ulipristal acetate on uterus leiomyomas as an additional sign to suspect leiomyosarcoma.
Kadhel P; Smail M; Borja De Mozota D
J Gynecol Obstet Hum Reprod; 2017 Sep; 46(7):609-611. PubMed ID: 28647614
[TBL] [Abstract][Full Text] [Related]
3. Unexpected Uterine Leiomyosarcoma During Laparoscopic Hysterectomy Treated 6Â Months With Ulipristal Acetate and Contained Power Morcellation.
Istre O
J Minim Invasive Gynecol; 2017 Feb; 24(2):198. PubMed ID: 27539216
[TBL] [Abstract][Full Text] [Related]
4. ACOG Committee Opinion No. 770: Uterine Morcellation for Presumed Leiomyomas.
Obstet Gynecol; 2019 Mar; 133(3):e238-e248. PubMed ID: 30801477
[TBL] [Abstract][Full Text] [Related]
5. In-bag manual versus uncontained power morcellation for laparoscopic myomectomy.
Zullo F; Venturella R; Raffone A; Saccone G
Cochrane Database Syst Rev; 2020 May; 5(5):CD013352. PubMed ID: 32374421
[TBL] [Abstract][Full Text] [Related]
6. Unexpected uterine leiomyosarcoma in a woman with multiple myomas treated with ulipristal acetate: case report and literature review.
Modaffari P; D'alonzo M; Garbagnati M; Pecchio S; Menato G; Biglia N
Gynecol Endocrinol; 2018 Mar; 34(3):192-194. PubMed ID: 28933575
[TBL] [Abstract][Full Text] [Related]
7. ACOG Committee Opinion No. 770 Summary: Uterine Morcellation for Presumed Leiomyomas.
Obstet Gynecol; 2019 Mar; 133(3):604-605. PubMed ID: 30801469
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms.
Seidman MA; Oduyebo T; Muto MG; Crum CP; Nucci MR; Quade BJ
PLoS One; 2012; 7(11):e50058. PubMed ID: 23189178
[TBL] [Abstract][Full Text] [Related]
9. Power morcellation-induced dissemination of sarcomatous component arising in leiomyoma.
Emoto I; Moriuchi K; Kanbayashi S; Inohaya A; Ri Y; Sato Y
J Obstet Gynaecol Res; 2018 Sep; 44(9):1843-1849. PubMed ID: 29974551
[TBL] [Abstract][Full Text] [Related]
10. Morcellating uterine mesenchymal tumors: The pathologist's view.
Pavlakis K; Messini I; Yiannou P; Gavresea T; Chrysanthakis D; Hilaris G; Panoskaltsis T
J Obstet Gynaecol Res; 2017 Mar; 43(3):580-586. PubMed ID: 28120430
[TBL] [Abstract][Full Text] [Related]
11. [Hysterectomies performed for presumed leiomyomas: should the fear of leiomyosarcoma make us apprehend non laparotomic surgical routes?].
Leung F; Terzibachian JJ; Gay C; Chung Fat B; Aouar Z; Lassabe C; Maillet R; Riethmuller D
Gynecol Obstet Fertil; 2009 Feb; 37(2):109-14. PubMed ID: 19200764
[TBL] [Abstract][Full Text] [Related]
12. Uterine leiomyosarcoma - incidence, treatment, and the impact of morcellation. A nationwide cohort study.
Skorstad M; Kent A; Lieng M
Acta Obstet Gynecol Scand; 2016 Sep; 95(9):984-90. PubMed ID: 27223683
[TBL] [Abstract][Full Text] [Related]
13. Being the ultimate travel companion of a patient with uterine leiomyosarcoma.
Grignani G; Merlini A; Aliberti S
Future Oncol; 2022 Sep; 18(29s):17-23. PubMed ID: 36169665
[TBL] [Abstract][Full Text] [Related]
14. Power Morcellation of Unsuspected High-grade Leiomyosarcoma Within an Inflated Containment Bag: 2-year Follow-up.
Boruta DM; Shibley T
J Minim Invasive Gynecol; 2016; 23(6):1009-11. PubMed ID: 27393286
[TBL] [Abstract][Full Text] [Related]
15. No. 371-Morcellation During Gynaecologic Surgery: Its Uses, Complications, and Risks of Unsuspected Malignancy.
Murji A; Scott S; Singh SS; Bougie O; Leyland N; Laberge PY; Vilos GA
J Obstet Gynaecol Can; 2019 Jan; 41(1):116-126. PubMed ID: 30580824
[TBL] [Abstract][Full Text] [Related]
16. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Ricci S; Stone RL; Fader AN
Gynecol Oncol; 2017 Apr; 145(1):208-216. PubMed ID: 28209496
[TBL] [Abstract][Full Text] [Related]
17. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.
Raine-Bennett T; Tucker LY; Zaritsky E; Littell RD; Palen T; Neugebauer R; Axtell A; Schultze PM; Kronbach DW; Embry-Schubert J; Sundang A; Bischoff K; Compton-Phillips AL; Lentz SE
Obstet Gynecol; 2016 Jan; 127(1):29-39. PubMed ID: 26646120
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and management experience of unexpected uterine sarcoma after myomectomy.
Zhang J; Zhang J; Dai Y; Zhu L; Lang J; Leng J
Int J Gynaecol Obstet; 2015 Aug; 130(2):195-9. PubMed ID: 26117552
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of unexpected leiomyosarcoma at myomectomy: a descriptive study.
Vercellini P; Cribiù FM; Bosari S; Scarfone G; Bolis G; Aimi G; Fedele L
Am J Obstet Gynecol; 2016 Feb; 214(2):292-294. PubMed ID: 26450408
[No Abstract] [Full Text] [Related]
20. A Multicentre Retrospective Review of Clinical Characteristics of Uterine Sarcoma.
Wais M; Tepperman E; Bernardini MQ; Gien LT; Jimenez W; Murji A
J Obstet Gynaecol Can; 2017 Aug; 39(8):652-658. PubMed ID: 28729098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
